DE NOVO PHARMACEUTICALS
De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.
DE NOVO PHARMACEUTICALS
Industry:
Health Care Life Science Medical Pharmaceutical
Founded:
1999-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Total Employee:
11+
Status:
Active
Contact:
+44 (0)1223 488888
Email Addresses:
[email protected]
Total Funding:
18.75 M GBP
Similar Organizations
Bard Pharmaceuticals
Bard Pharmaceuticals is a healthcare products manufacturing company.
Elpen Pharmaceutical
Elpen Pharmaceutical is a pharmaceutical company.
Pace Analytical Services
Pace Analytical is a leader in integrated drug development.
Tagworks Pharmaceuticals
Tagworks Pharmaceuticals is a privately held biotech company
Investors List
Roche Venture Fund
Roche Venture Fund investment in Series B - De Novo Pharmaceuticals
Quester
Quester investment in Series B - De Novo Pharmaceuticals
The Cambridge Gateway Fund
The Cambridge Gateway Fund investment in Series B - De Novo Pharmaceuticals
FNI Venture Capital
FNI Venture Capital investment in Series B - De Novo Pharmaceuticals
MVM Life Science Partners
MVM Life Science Partners investment in Series B - De Novo Pharmaceuticals
Merlin Biomed
Merlin Biomed investment in Series B - De Novo Pharmaceuticals
Avlar BioVentures
Avlar BioVentures investment in Series B - De Novo Pharmaceuticals
Incyte
Incyte investment in Series B - De Novo Pharmaceuticals
Prelude Trust
Prelude Trust investment in Series B - De Novo Pharmaceuticals
Prelude Trust
Prelude Trust investment in Series A - De Novo Pharmaceuticals
More informations about "De Novo Pharmaceuticals"
DE NOVO PHARMACEUTICALS LIMITED - Companies House
More for DE NOVO PHARMACEUTICALS LIMITED (03761178) Registered office address Gilmarde House, 47 South Bar Street, Banbury, Oxfordshire, England, OX16 9AB . Company …See details»
De Novo Pharmaceuticals - LinkedIn
De Novo Pharmaceuticals Ltd, a fully integrated design-based drug discovery company located in Cambridge UK, uses its proprietary computational software for drug design to create novel, patentable ...See details»
De Novo Pharmaceuticals - PitchBook
Jul 22, 2001 De Novo Pharmaceuticals General Information Description. Provider of a drug discovery platform designed to provide computerized drug …See details»
De Novo Pharmaceuticals Ltd. - Drug pipelines, Patents, Clinical …
Explore De Novo Pharmaceuticals Ltd. with its drug pipeline, therapeutic area, technology platform, 29 literature, Disease Domain:Neoplasms, Technology Platform:Small molecule …See details»
DE NOVO PHARMACEUTICALS LIMITED - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for DE NOVO PHARMACEUTICALS LIMITED of BANBURY. Get the latest business insights from Dun & …See details»
De Novo Pharmaceuticals - Funding, Financials, Valuation
De Novo Pharmaceuticals is an emerging computational drug design company. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. Experience the …See details»
De Novo Pharmaceuticals Limited - Company Profile - Endole
Apr 28, 1999 De Novo Pharmaceuticals Limited is an active company incorporated on 28 April 1999 with the registered office located in Banbury, Oxfordshire. De Novo Pharmaceuticals …See details»
De Novo Pharmaceuticals Ltd - Company Profile and News
Company profile page for De Novo Pharmaceuticals Ltd including stock price, company news, executives, board members, and contact informationSee details»
De Novo Pharmaceuticals - Crunchbase
De Novo Pharmaceuticals is an emerging computational drug design company.See details»
De Novo Pharmaceuticals - Company Profile - Tracxn
Feb 22, 2025 De Novo Pharmaceuticals - Provider of computational drug design software and services. This company is not active anymore. Raised a total funding of $23.9M over 2 rounds …See details»
De Novo Pharmaceuticals Ltd.:Company Profile & Technical …
De Novo Pharmaceuticals Ltd. is a company that provides Drug design, Biology, Medicine and more. De Novo Pharmaceuticals Ltd. is headquartered in United Kingdom Cambridgeshire. De …See details»
De Novo Pharmaceuticals - Overview, News & Similar companies
De Novo Pharmaceuticals is a fully integrated design based drug discovery company, located in Cambridge, UK, and uses its proprietary computational software for drug design to create …See details»
De Novo Pharmaceuticals - VentureRadar
De Novo’s technology offers the following advantages to drug developers: lower cost – in-silico design reduces wasted effort in synthesis and HTS; rapid – typically less than 6 months target …See details»
De Novo Pharmaceuticals - Products, Competitors, Financials, …
De Novo Pharmaceuticals Ltd is a computationally-based drug discovery company focused on small molecule therapeutics. De Novo develops a suite of structure-generating programs …See details»
De Novo Pharmaceuticals - SelectScience
A more rational approach to drug design De Novo is a world leader in in-silico, de novo drug design.De Novo’s technology offers the following advantages to drug developers:-. lower cost …See details»
De Novo Pharmaceuticals announces drug design and discovery …
Mar 12, 2001 De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De …See details»
What is De Novo Pharmaceuticals? Company Culture, Mission, …
See what employees say it's like to work at De Novo Pharmaceuticals. Salaries, reviews, and more - all posted by employees working at De Novo Pharmaceuticals.See details»
5 Key Differences Between De Novo and 510(k) Submissions You …
Jan 7, 2025 The de novo 510 k application and the 510(k) application signify two crucial routes for obtaining FDA approval for medical instruments, each fulfilling different roles in the …See details»
GraphChem: Using Soft Graph Mixture of Experts for de novo …
Feb 20, 2025 It has been benchmarked on GuacaMole, DOCKSTRING and others for de novo drug design, and MoleculeNet and DOCSTIRNG tasks for molecular property prediction. …See details»
Drug-coated balloons in small vessel de novo coronary artery …
Feb 28, 2025 The treatment of de novo coronary artery disease with DCBs has been less well studied, but is an area of growing interest. On one hand, the avoidance of even a first layer of …See details»